These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31325017)

  • 1. Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy.
    Herraets IJT; Bakers JNE; van Eijk RPA; Goedee HS; van der Pol WL; van den Berg LH
    J Neurol; 2019 Nov; 266(11):2734-2742. PubMed ID: 31325017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
    Speth F; Haas JP; Hinze CH
    Pediatr Rheumatol Online J; 2016 Sep; 14(1):52. PubMed ID: 27623619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
    Hahn AF; Beydoun SR; Lawson V; ; Oh M; Empson VG; Leibl H; Ngo LY; Gelmont D; Koski CL
    J Peripher Nerv Syst; 2013 Dec; 18(4):321-30. PubMed ID: 24725024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
    Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M
    J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy.
    Vlam L; Cats EA; Willemse E; Franssen H; Medic J; Piepers S; Veldink JH; van den Berg LH; van der Pol WL
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1145-8. PubMed ID: 24336791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial.
    Kuwabara S; Misawa S; Mori M; Iwai Y; Ochi K; Suzuki H; Nodera H; Tamaoka A; Iijima M; Toda T; Yoshikawa H; Kanda T; Sakamoto K; Kusunoki S; Sobue G; Kaji R;
    J Peripher Nerv Syst; 2018 Jun; 23(2):115-119. PubMed ID: 29635876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
    Léger JM; Chassande B; Musset L; Meininger V; Bouche P; Baumann N
    Brain; 2001 Jan; 124(Pt 1):145-53. PubMed ID: 11133794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy.
    Al-Zuhairy A; Sindrup SH; Jakobsen J
    J Neurol Sci; 2021 Aug; 427():117495. PubMed ID: 34023695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
    Gorson KC; Natarajan N; Ropper AH; Weinstein R
    Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
    Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
    J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy.
    Bakers JNE; van Eijk RPA; van den Berg LH; Visser-Meily JMA; Beelen A
    Muscle Nerve; 2021 May; 63(5):678-682. PubMed ID: 33501670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.
    Harbo T; Andersen H; Hess A; Hansen K; Sindrup SH; Jakobsen J
    Eur J Neurol; 2009 May; 16(5):631-8. PubMed ID: 19236457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort.
    Yalcin Gungoren E; Yorgun Altunbas M; Dikici U; Meric Z; Eser Simsek I; Kiykim A; Can S; Karabiber E; Yakici N; Orhan F; Cokugras H; Aydogan M; Ozdemir O; Bilgic Eltan S; Baris S; Ozen A; Karakoc-Aydiner E
    J Clin Immunol; 2024 Aug; 44(8):169. PubMed ID: 39098942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
    Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
    Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
    Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
    J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
    Harbo T; Andersen H; Jakobsen J
    Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
    Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
    Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy.
    Chaudhry V; Cornblath DR
    J Peripher Nerv Syst; 2010 Sep; 15(3):196-201. PubMed ID: 21040141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.